BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:27 PM
 | 
Sep 20, 2007
 |  BC Extra  |  Clinical News

Viviant meets osteoporosis endpoint

Wyeth (WYE) said 20 and 40 mg of Viviant bazedoxifene met the primary endpoint of reducing the incidence of new vertebral fractures after 36 months vs. placebo in a Phase III trial to treat osteoporosis. In the double-blind...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >